| Autor: |
Wan Hsi Chen, Monish Ram Makena, Aaron Smith, Venkatesh Pilla Reddy, Reynolds Cp, Eslinger C, Balakrishna Koneru, Burrow Ta, Joanne Wilson, Steve T. Durant, Elaine Cadogan, Ashly Hindle, Thinh H. Nguyen, Ahsan Farooqi |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.04.06.438692 |
| Popis: |
Cancers overcome replicative immortality by activating either telomerase or an alternative lengthening of telomeres (ALT) mechanism. ALT occurs in ∼ 25% of high-risk neuroblastomas and relapse or progression in ALT neuroblastoma patients during or after front-line therapy is frequent and almost uniformly fatal. Temozolomide + irinotecan is commonly used as salvage therapy for neuroblastoma. Patient-derived cell-lines and xenografts established from relapsed ALT neuroblastoma patients demonstratedde novoresistance to temozolomide + irinotecan (as SN-38in vitro, P)andin vivo(mouse event-free survival (EFS)PPin vitro(Pin vivo(EFSPOne Statement SummaryATM activation at telomeres confers resistance to DNA damaging chemotherapy in ALT neuroblastoma that was reversed with ATM knockdown or inhibition. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
